|
|||||
|
|
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease |
|
| Institution: | 1. Centre for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, Neuroscience Section, University of Salerno, Salerno, Italy;2. Neuropsychology Laboratory, Department of Psychology, Second University of Naples, Caserta, Italy;3. Sobell Department of Motor Neuroscience and Movement Disorders, University College London (UCL) Institute of Neurology, London, UK;4. Dipartimento di Scienze Neurologiche e del Movimento, Università di Verona, Verona, Italy;5. IDC Hermitage-Capodimonte, Naples, Italy;6. University of Naples Parthenope, Naples, Italy;1. Department of Pharmacology, Medical College of Wuhan University of Science and Technology, Wuhan 430080, PR China;2. Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, PR China;1. Department of Neurology, Geneva University Hospitals, Switzerland;2. Department of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Switzerland;3. Faculty of Medicine, University of Geneva, Switzerland;4. Physiology Unit, Department of Medicine, University of Fribourg, Switzerland;1. Genetic Epidemiology, Institute for Human Genetics, Westfälische Wilhelms University, Muenster, Germany;2. Children''s Hospital, University Hospital Frankfurt, Frankfurt, Germany;3. Pediatric Hematology and Oncology, University Hospital of Muenster, Muenster, Germany;4. Division of Hematology and Oncology, Department of Medicine A, University Hospital of Muenster, Muenster, Germany;5. Institute for Molecular Biology, Christian-Albrechts University Kiel, Kiel, Germany;6. Institute of Epidemiology and Biobank PopGen, Christian-Albrechts University Kiel, Kiel, Germany;7. Thrombosis & Hemostasis Treatment Center, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Lubeck, Germany;8. Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;1. Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland;2. Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland |
| Abstract: | ObjectivesTo explore the relationships between nigrostriatal dysfunction and neuropsychiatric symptoms (including anxiety, depression and apathy) in a large cohort of newly diagnosed, drug-naïve Parkinson disease (PD) patients compared to a cohort of healthy controls (HC).MethodsThis is a cross-sectional analysis of the Parkinson's Progression Markers Initiative (PPMI) cohort at baseline, including 405 PD patients and 187 HC. Nigrostriatal degeneration was evaluated by means of SPECT DAT scan. Relationships between neuropsychiatric symptoms and DAT uptakes were analysed by means of stepwise multiple regression analysis.ResultsIn the PD group, lower DAT uptake in the right caudate was associated with higher STAI trait subscore (β = ?2.939, 95%CI: ?4.634 to ?1.254, p = 0.001). Depression and apathy scores were not related with DAT uptakes. No associations were found in the HC group.ConclusionsOur cross-sectional analysis of the PPMI data shows that lower caudate DAT uptake is associated with higher level of anxiety. The data strengthens the relationship between dopaminergic dysfunction and neuropsychiatric symptoms in early PD. |
| Keywords: | Parkinson's disease Anxiety Dopaminergic Non motor symptoms Apathy Depression DAT SPECT DAT"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"dopamine transporter GDS-15"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"15-item Geriatric Depression Scale HC"} {"#name":"keyword" "$":{"id":"kwrd0075"} "$$":[{"#name":"text" "_":"healthy controls MDS-UPDRS"} {"#name":"keyword" "$":{"id":"kwrd0085"} "$$":[{"#name":"text" "_":"Movement Disorder Society-Unified Parkinson's Disease Rating Scale PD"} {"#name":"keyword" "$":{"id":"kwrd0095"} "$$":[{"#name":"text" "_":"Parkinson’ s disease PPMI"} {"#name":"keyword" "$":{"id":"kwrd0105"} "$$":[{"#name":"text" "_":"Parkinson's Progression Markers initiative SBRs"} {"#name":"keyword" "$":{"id":"kwrd0115"} "$$":[{"#name":"text" "_":"striatal binding ratios SD"} {"#name":"keyword" "$":{"id":"kwrd0125"} "$$":[{"#name":"text" "_":"standard deviation SPECT"} {"#name":"keyword" "$":{"id":"kwrd0135"} "$$":[{"#name":"text" "_":"single positron emission computerized tomography STAI"} {"#name":"keyword" "$":{"id":"kwrd0145"} "$$":[{"#name":"text" "_":"State-Trait Anxiety Inventory |
| 本文献已被 ScienceDirect 等数据库收录！ | |